NorthStrive amends license deal with MOA Life Plus for muscle assets

NorthStrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), signed a third amendment to its licensing agreement with Korean biotechnology company MOA Life Plus Co. Ltd. (KOSDAQ: 142760) for assets EL-32 and EL-22.

The amendment updates timing and development milestones for human clinical development programs of both assets, according to a company statement. The changes align the schedule with research and development and regulatory expectations of both parties.

NorthStrive's lead asset EL-22 uses an engineered probiotic approach to address muscle preservation during weight loss treatments, including GLP-1 receptor agonists. The company focuses on developing aesthetic medicines through its biopharmaceutical operations.

MOA Life Plus operates as a biotechnology company in Korea, focusing on research and development of therapeutic and wellness technologies. The company partners globally for scientific innovation in human and animal health applications.

PMGC Holdings operates as a diversified holding company managing portfolios through acquisitions, investments, and development across multiple industries.

You May Also Be Interested In

• Tango Therapeutics adds Robert Azelby to its board of directors
• Seadrill extends $500M share repurchase program to end of 2026
• Lion Group to acquire 10% stake in Indonesian stablecoin firm via shares